Literature Review: Development of Antiretroviral Therapy in Hiv/Aids Treatment
Abstract
Human Immunodeficiency Virus (HIV) is a virus that attacks the human immune system. The United Nations Joint Program for HIV/AIDS (UNAIDS) in 2019, stated that the largest HIV-infected population in the world is on the African continent (25.7 million), then in Southeast Asia (3.8 million), and in the Americas (3.5 million). HIV/AIDS symptoms consist of 4 stages, namely stage 1, this phase is referred to as asymptomatic HIV infection where the initial HIV symptoms are still not felt. The goal of antiretroviral therapy (ARV) is to increase the number of CD4+ in T cells, reduce viral load, so that it is expected to reduce mortality. Recommendations for ARV administration are always evolving. Currently, ARVs are given to patients with PLWHA at any clinical stage and CD4+ count. This study aims to determine the development of Antiretroviral therapy (ARV) in the treatment of HIV/AIDS. The method used was literature review with narrative review design to identify and summarise previously published articles on the development of Antiretroviral (ARV) therapy in the treatment of HIV/AIDS. From the 10 articles summarised, it was found that there was an influence of the development of Antiretroviral (ARV) therapy in the treatment of HIV/AIDS over time.
References
Addisu, T., Tilahun, M., Wedajo, S., & Sharew, B. (2023). Trends Analysis of HIV Infection and Antiretroviral Treatment Outcome in Amhara Regional from 2015 to 2021, Northeast Ethiopia. HIV/AIDS – Research and Palliative Care, 15, 1–10. https://doi.org/10.2147/HIV.S411235DO
Agung, R., Paradissa, L. V. (2024). Implementasi Kebijakan Penanggulangan HIV/AIDS: Tantangan dan Hambatan pada Transpuan di Yogyakarta. Prosiding SENAPAS.
Ahmed, I., Demissie, M., Worku, A., Gugsa, S., & Berhane, Y. (2020). Effectiveness of same-day antiretroviral therapy initiation in retention outcomes among people living with human immunodeficiency virus in Ethiopia: empirical evidence. BMC Public Health, 20(1), 1802. https://doi.org/10.1186/s12889-020-09887-9
Balatif, R. (2020). HIV Infection: What Should We Know?. Journal of Endocrinology, Tropical Medicine, and Infectious Disease (JETROMI), 2(1), 01-16. https://doi.org/10.32734/jetromi.v2i1.2038
Brima, Y., Atemkeng, M., Tankio Djiokap, S., Ebiele, J., & Tchakounté, F. (2021). Transfer learning for the detection and diagnosis of types of pneumonia including pneumonia induced by COVID-19 from chest X-ray images. Diagnostics, 11(8), 1480. https://doi.org/10.3390/diagnostics11081480
Charpentier, C., Le Hingrat, Q., Ferré, V. M., Damond, F., & Descamps, D. (2023). Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance. Viruses, 15(2), 453. https://doi.org/10.3390/v15020453
Edelman, A. S., & Zolla‐Pazner, S. (1989). AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency. The FASEB journal, 3(1), 22-30. https://doi.org/10.1096/fasebj.3.1.2562947
Elendu, C., Amaechi, D. C., Elendu, T. C., Amaechi, E. C., Elendu, I. D., Akpa, K. N., ... & Idowu, O. F. (2025). Shaping sustainable paths for HIV/AIDS funding: a review and reminder. Annals of Medicine and Surgery, 87(3), 1415-1445. https://doi.org/10.1097/ms9.0000000000002976
Febriani, D. M., Lukas, S., & Murtiani, F. (2019). Evaluasi Penggunaan Antiretroviral (ARV) Berdasarkan Indikator CD4 Pada Pasien HIV di RSPI Prof. Dr. Sulianti Saroso. The Indonesian Journal of Infectious Diseases, 5(2), 21–30. https://doi.org/10.32667/ijid.v5i2.85
Gebremichael, M. A., Gurara, M. K., & Weldehawaryat, H. N. (2020). Incidence and predictors of initial antiretroviral therapy regimen change among HIV-infected adults receiving antiretroviral therapy at Arba Minch General Hospital, Southern Ethiopia. HIV/AIDS – Research and Palliative Care, 12, 315–329. https://doi.org/10.2147/HIV.S254386
Kaudha, R., Amanya, R., Kakuru, D., Atwooki, R. M., Muyoozi, R. M., Wagubi, R., Muwanguzi, E., & Okongo, B. (2023). Anemia in HIV Patients Attending Highly Active Antiretroviral Therapy Clinic at Hoima Regional Referral Hospital: Prevalence, Morphological Classification, and Associated Factors. HIV/AIDS – Research and Palliative Care, 15, 621–632. https://doi.org/10.2147/HIV.S425807
Kemnic, T. R., & Gulick, P. G. (2025). HIV Antiretroviral Therapy. In StatPearls. Treasure Island (FL): StatPearls Publishing. Tersedia di: NCBI Bookshelf
Lailiah, N., Nursalam, N., & Indarwati, R. (2024). Development of resilience model in people with human immunodeficiency virus undergoing antiretroviral therapy. International Journal of Public Health Science, 13(3), 1087–1094. https://doi.org/10.11591/ijphs.v13i3.23746
Li, Y., Wang, Q., Liang, S., Feng, C., Yang, H., Yu, H., Yuan, D., & Yang, S. (2022). Effect of switching antiretroviral treatment regimen in patients with drug-resistant HIV-1 infection: Retrospective observational cohort study. JMIR Public Health and Surveillance, 8(6), e33429. https://doi.org/10.2196/33429
Lyatuu, G. W., Mwashemele, S. Z., Urrio, R., Naburi, H., Kashmir, N., Machumi, L., ... & Ekström, A. M. (2021). Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study. The lancet HIV, 8(5), e256-e265. https://doi.org/10.1016/s2352-3018(20)30308-8
Natasya Natasya, Shella Nur Maharani, & Misna Misna. (2024). HIV/AIDS : Update Terkini di Indonesia. Protein : Jurnal Ilmu Keperawatan Dan Kebidanan. , 3(1), 27–36. https://doi.org/10.61132/protein.v3i1.918
Nayan, M. U., Sillman, B., Hasan, M., Deodhar, S., Das, S., Sultana, A., Thai Hoang Le, N., Soriano, V., Edagwa, B., & Gendelman, H. E. (2023). Advances in Long-Acting Slow Effective Release Antiretroviral Therapies for Treatment and Prevention of HIV Infection. Advanced Drug Delivery Reviews, 200, 115009. https://doi.org/10.1016/j.addr.2023.115009
Ndashimye, E., Reyes, P. S., & Arts, E. J. (2023). New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates? FEMS Microbiology Reviews, 47(1), fuac040. https://doi.org/10.1093/femsre/fuac040
Nuwagaba, J., Li, J. A., Ngo, B., & Sutton, R. E. (2025). 30 Years of HIV Therapy: Current and Future Antiviral Drug Targets. Virology, 603, 110362. https://doi.org/10.1016/j.virol.2024.110362
Qu, S., Wang, Q., Wang, X., Qiao, Y., Yao, J., Li, Z., ... & Wang, A. (2023). Recommend guideline on prevention of mother-to-child transmission of HIV in China in 2020. Infectious Diseases & Immunity, 3(02), 52-59. https://doi.org/10.1097/ID9.0000000000000083
Rifqian, N., & Mediana, D. (2024). HIV/AIDS Knowledge Improves Antiretroviral Drug Compliance. Pendidikan Kesehatan, 9(2), 357–369. https://doi.org/10.25105/pdk.v9i2.19312
Riono, P., & Challacombe, S. J. (2020). HIV in Indonesia and in neighbouring countries and its social impact. Oral diseases, 26, 28-33. https://doi.org/10.1111/odi.13560
Saniputra, A. A. (2022). Meta Analisis Beda Rata-Rata Pada Pengobatan HIV/AIDS Di Indonesia. Preventif: Jurnal Kesehatan Masyarakat, 13(4), 538–548. https://doi.org/10.22487/preventif.v13i4.431
Shu, W., Du, F., & Duan, K. (2022). A Real-world Evidence-based Management of HIV by Differential Duration HAART Treatment and its Association with Incidence of Oral Lesions. Current HIV Research, 20(1), 91–99. https://doi.org/10.2174/1570162X20666211227154558
Shumetie, A., Moges, N. A., Teshome, M., & Gedif, G. (2021). Determinants of Virological Failure Among HIV-Infected Children on First-Line Antiretroviral Therapy in West Gojjam Zone, Amhara Region, Ethiopia. HIV/AIDS – Research and Palliative Care, 13, 1035–1044. https://doi.org/10.2147/HIV.S334067
Simooya, C., Silumbwe, A., Halwindi, H., Zulu, J. M., & Nzala, S. (2023). Exploring communication and implementation challenges of the HIV/AIDS policy change to test-and-treat-all in selected public health facilities in Lusaka District, Zambia. Implementation Science Communications, 4(1), 51. https://doi.org/10.1186/s43058-023-00430-6
Teshale, A. B., Tsegaye, A. T., & Wolde, H. F. (2021). Incidence of Mortality and Its Predictors Among HIV Positive Adults on Antiretroviral Therapy in University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. HIV/AIDS – Research and Palliative Care, 13, 31–39. https://doi.org/10.2147/HIV.S289794
Tiffany, E., & Yuniartika, W. (2023). Efektivitas Terapi Antiretroviral terhadap Pasien HIV (Literature Review). Jurnal Multidisiplin West Science, 2(5), 364–373. https://doi.org/10.58812/jmws.v2i5.346
Vanangamudi, M., Palaniappan, S., Kathiravan, M. K., & Namasivayam, V. (2023). Strategies in the design and development of non-nucleoside reverse transcriptase inhibitors (NNRTIs). Viruses, 15(10), 1992. https://doi.org/10.3390/v15101992
Vojnov, L., Carmona, S., Zeh, C., Markby, J., Boeras, D., Prescott, M. R., ... & DBS for VL Diagnostics Investigation Consortium. (2022). The performance of using dried blood spot specimens for HIV-1 viral load testing: a systematic review and meta-analysis. PLoS Medicine, 19(8), e1004076. https://doi.org/10.1371/journal.pmed.1004076
Wahyuni, N. W. S., Negara, I. M. K., & Putra, I. B. A. (2023). Hubungan Pengetahuan Ibu Hamil Tentang HIV/AIDS Dengan Minat Ibu Hamil Melakukan Voluntary Counselling And Testing (VCT) Di Puskesmas Ubud II. Jurnal Riset Kesehatan Nasional, 7(1), 21–27. https://doi.org/10.37294/jrkn.v7i1.441
Widjaja, M. C. G. (2022). Rejimen KDT-ARV Terbaru dengan Dolutegravir. Cermin Dunia Kedokteran, 49(6), 314–319. https://doi.org/10.55175/cdk.v49i6.239
World Health Organization. (2023). The role of HIV viral suppression in improving individual health and reducing transmission: policy brief. World Health Organization.
Yang, Y., Li, Y., Zhang, X., Zhang, W., Ma, Y., Jia, X., Gondwe, T., Wang, Y., & Shi, X. (2021). Effect of antiretroviral therapy initiation time and baseline CD4⁺ cell counts on AIDS-related mortality among former plasma donors in China: a 21-year retrospective cohort study. Global Health Action, 14(1), 1963527. https://doi.org/10.1080/16549716.2021.1963527
Yoo, S. W., Waheed, A. A., Deme, P., Tohumeken, S., Rais, R., Smith, M. D., ... & Haughey, N. J. (2023). Inhibition of neutral sphingomyelinase 2 impairs HIV-1 envelope formation and substantially delays or eliminates viral rebound. Proceedings of the National Academy of Sciences, 120(28), e2219543120. https://doi.org/10.1371/journal.pmed.1004076
Copyright (c) 2025 Journal La Medihealtico
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
